Tissue-source effect on mesenchymal stem cells as living biodrugs for heart failure: Systematic review and meta-analysis

doi:10.4330/wjc.v16.i8.469

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (229)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-5) series.

Item

Count

PDF

HTML

184

Figures (1-5)

Tables (1-5)

Sum=205

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=9

Publishing Process of This Article

Item

Count

Browse

Download

Sum=3

Aug 26, 2024 (publication date) through Aug 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Cardiol. Aug 26, 2024; 16(8): 469-483
Published online Aug 26, 2024. doi: 10.4330/wjc.v16.i8.469

Table 4 Intervention characteristics of randomized controlled trials of umbilical-cord-derived mesenchymal stem cells

Refs	Cell type	Cell condition	MSCs dose and volume	Route of delivery	Concurrent procedure (if any)
He et al[18]	WJUC-MSCs	Frozen	1 × 10⁸/1.5-2.5 mL +/- 1 mL collagen scaffold	IM	CABG for all groups
Zhao et al[26]	UC-MSCs	N/S	N/S	IC	N/A
Bartolucci et al[28]	WJUC-MSCs	Frozen	1 × 10⁶/kg in 100 mL	IV	N/A
Ulus et al[25]	UC-MSCs	Frozen	23 × 10⁶	IM	CABG for all groups
Gao et al[21]	WJUC- MSCs	Fresh	6 × 10⁶	IC	N/A

CABG: Coronary artery bypass grafting; N/A: Not available; N/S: Not specified; IC: Intracoronary; IM: Intramyocardial; IV: Intravenous; PCI: Percutaneous coronary intervention; WJUC-MSCs: Wharton’s Jelly umbilical cord mesenchymal stem cells; UC-MSCs: Umbilical cord-derived mesenchymal stem cells; MSCs: Mesenchymal stem cells.

Citation: Safwan M, Bourgleh MS, Aldoush M, Haider KH. Tissue-source effect on mesenchymal stem cells as living biodrugs for heart failure: Systematic review and meta-analysis. World J Cardiol 2024; 16(8): 469-483
URL: https://www.wjgnet.com/1949-8462/full/v16/i8/469.htm
DOI: https://dx.doi.org/10.4330/wjc.v16.i8.469